Evidence map›Paper›PMID 29113995›Full record

ReviewJournal of clinical pathology2018

Time for change: a new training programme for morpho-molecular pathologists?

David A Moore, Caroline A Young, Hayley T Morris, Karin A Oien, Jessica L Lee, J Louise Jones, Manuel Salto-Tellez

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of clinical pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

David A MooreDepartment of Cancer Studies, University of Leicester, Leicester, UK.
Caroline A Young *School of Medicine, St James' University Hospital, Leeds, UK.
Hayley T Morris *Institute of Cancer Sciences - Pathology, University of Glasgow, Glasgow, UK.
Karin A OienInstitute of Cancer Sciences - Pathology, University of Glasgow, Glasgow, UK.
Jessica L LeeStrategy and Initiatives, National Cancer Research Institute, London, UK.
J Louise JonesCentre for Tumour Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, London, UK.
Manuel Salto-TellezNorthern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK.
Institute of Cancer Research · CACancer Institute (WIA) · INNational Cancer Research Institute · GBQueen's University Belfast · GBSt James's University Hospital · GBUniversity of Leicester · GB

Funding

Medical Research Council MR/N005813/1Wellcome Trust 203524/Z/16/Z
6 · The paper itself

Abstract

The evolution of cellular pathology as a specialty has always been driven by technological developments and the clinical relevance of incorporating novel investigations into diagnostic practice. In recent years, the molecular characterisation of cancer has become of crucial relevance in patient treatment both for predictive testing and subclassification of certain tumours. Much of this has become possible due to the availability of next-generation sequencing technologies and the whole-genome sequencing of tumours is now being rolled out into clinical practice in England via the 100 000 Genome Project. The effective integration of cellular pathology reporting and genomic characterisation is crucial to ensure the morphological and genomic data are interpreted in the relevant context, though despite this, in many UK centres molecular testing is entirely detached from cellular pathology departments. The CM-Path initiative recognises there is a genomics knowledge and skills gap within cellular pathology that needs to be bridged through an upskilling of the current workforce and a redesign of pathology training. Bridging this gap will allow the development of an integrated 'morphomolecular pathology' specialty, which can maintain the relevance of cellular pathology at the centre of cancer patient management and allow the pathology community to continue to be a major influence in cancer discovery as well as playing a driving role in the delivery of precision medicine approaches. Here, several alternative models of pathology training, designed to address this challenge, are presented and appraised.

Indexed as

HumansPathologistsPathology, Molecularcancerdiagnosticshistopathologymolecular pathologymorphology

Identifiers

PMID29113995
PMCPMC5868526
OpenAlexW2767699080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.